Lezogaberan

Lezogaberan
	((R)-3-Amino-2-fluoropropil)fosfinska kiselina
Drugi nazivi	AZD-3355
Identifikacija
CAS registarski broj	344413-67-8
PubChem	9833984
UNII	4D6Q6HGC7Z
ChEMBL	CHEMBL448343
Jmol-3D slike	Slika 1
SMILES
	O=P([H])(C[C@@H](CN)F)O
Svojstva
Molekulska formula	C3H9FNO2P
Molarna masa	141.08 g mol−1
	(šta je ovo?) (verifikuj) ; Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje (25 °C, 100 kPa) materijala
	Infobox references

Lezogaberan (AZD-3355) je^[4] eksperimentalni lek za tretiranje gastroesofagealna refluksne bolesti.^[5] On je agonist GABA_B receptora,^[6] i ima isti mehanizam dejstva kao i baklofen, ali se očekuje da će imati manje nuspojava vezanih za centralni nervni sistem, koje ograničavaju kliničku primenu baklofena.^[7]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ AstraZeneca. „AZD3355”. Arhivirano iz originala na datum 2012-04-26. Pristupljeno 30. 12. 2011.
↑ Bredenoord, Albert J. (2009). „Lesogaberan, a GABA_B agonist for the potential treatment of gastroesophageal reflux disease”. IDrugs 12 (9): 576–584. PMID 19697277.
↑ Alstermark, et al.; Amin, K; Dinn, SR; Elebring, T; Fjellström, O; Fitzpatrick, K; Geiss, WB; Gottfries, J i dr.. (2008). „Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors”. Journal of Medicinal Chemistry 51 (14): 4315–4320. DOI:10.1021/jm701425k. PMID 18578471.
↑ Brian E. Lacy, Robert Chehade, and Michael D. Crowell (2010). „Lesogaberan”. Drugs of the Future 35 (12): 987–992. DOI:10.1358/dof.2010.035.012.1540661.

Spoljašnje veze uredi

Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] AstraZeneca. „AZD3355”. Arhivirano iz originala na datum 2012-04-26. Pristupljeno 30. 12. 2011.

[5] Bredenoord, Albert J. (2009). „Lesogaberan, a GABA_B agonist for the potential treatment of gastroesophageal reflux disease”. IDrugs 12 (9): 576–584. PMID 19697277.

[6] Alstermark, et al.; Amin, K; Dinn, SR; Elebring, T; Fjellström, O; Fitzpatrick, K; Geiss, WB; Gottfries, J i dr.. (2008). „Synthesis and Pharmacological Evaluation of Novel γ-Aminobutyric Acid Type B (GABAB) Receptor Agonists as Gastroesophageal Reflux Inhibitors”. Journal of Medicinal Chemistry 51 (14): 4315–4320. DOI:10.1021/jm701425k. PMID 18578471.

[7] Brian E. Lacy, Robert Chehade, and Michael D. Crowell (2010). „Lesogaberan”. Drugs of the Future 35 (12): 987–992. DOI:10.1358/dof.2010.035.012.1540661.

[4]

[5]

[6]

[7]

[1]

[2]

[3]